Deep vein thrombosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
|||
| (11 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
'''Editor(s)-In-Chief:''' {{ATI}}, [[C. Michael Gibson, M.S., M.D.]] [mailto: | __NOTOC__ | ||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Siren.gif|30px|link=Deep vein thrombosis resident survival guide]]|| <br> || <br> | |||
| [[Deep vein thrombosis resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
'''Editor(s)-In-Chief:''' {{ATI}}, [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]; '''Associate Editor(s)-In-Chief:''' {{CZ}} [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org]; [[User:Kashish Goel|Kashish Goel, M.D.]]; '''Assistant Editor(s)-In-Chief:''' [[User:Justine Cadet|Justine Cadet]] | |||
{{Deep vein thrombosis}} | {{Deep vein thrombosis}} | ||
==Overview== | ==Overview== | ||
In United States, [[deep vein thrombosis]] DVT and [[pulmonary embolism]] PE costs are<ref name="pmid17672809">{{cite journal| author=Spyropoulos AC, Lin J| title=Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. | journal=J Manag Care Pharm | year= 2007 | volume= 13 | issue= 6 | pages= 475-86 | pmid=17672809 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17672809 }} </ref> | In the United States, [[deep vein thrombosis]] DVT and [[pulmonary embolism]] PE costs are more than $9,800 and $14,000 for initial hospitalization respectively, and more than $11,800 and $14,700 for rehospitalization (over half of which occurs within 90 days), respectively.<ref name="pmid17672809">{{cite journal| author=Spyropoulos AC, Lin J| title=Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. | journal=J Manag Care Pharm | year= 2007 | volume= 13 | issue= 6 | pages= 475-86 | pmid=17672809 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17672809 }} </ref> Several studies have reported that prophylaxis therapy against VTE among surgical patients is cost effective.<ref name="pmid10169385">{{cite journal| author=Anderson DR, O'Brien BJ| title=Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. | journal=Pharmacoeconomics | year= 1997 | volume= 12 | issue= 1 | pages= 17-29 | pmid=10169385 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10169385 }} </ref> According to the Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt [[enoxaparin]] prophylaxis against DVT after total hip replacement.<ref name="pmid8137188">{{cite journal |author=O'Brien BJ, Anderson DR, Goeree R |title=Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement |journal=CMAJ |volume=150 |issue=7 |pages=1083–90 |year=1994 |month=April |pmid=8137188 |pmc=1486381 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Needs overview]] | |||
[[Category:Disease]] | |||
[[Category:Cardiology]] | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Angiology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Vascular surgery]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Cardiovascular diseases]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:26, 16 July 2014
 |
Resident Survival Guide |
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis cost-effectiveness of therapy On the Web |
|
Deep vein thrombosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Deep vein thrombosis cost-effectiveness of therapy |
Overview
In the United States, deep vein thrombosis DVT and pulmonary embolism PE costs are more than $9,800 and $14,000 for initial hospitalization respectively, and more than $11,800 and $14,700 for rehospitalization (over half of which occurs within 90 days), respectively.[1] Several studies have reported that prophylaxis therapy against VTE among surgical patients is cost effective.[2] According to the Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.[3]
References
- ↑ Spyropoulos AC, Lin J (2007). "Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations". J Manag Care Pharm. 13 (6): 475–86. PMID 17672809.
- ↑ Anderson DR, O'Brien BJ (1997). "Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism". Pharmacoeconomics. 12 (1): 17–29. PMID 10169385.
- ↑ O'Brien BJ, Anderson DR, Goeree R (1994). "Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement". CMAJ. 150 (7): 1083–90. PMC 1486381. PMID 8137188. Unknown parameter
|month=ignored (help)